Back to today’s briefing

Story perspectives

FDA Rejects Atara's Ebvallo Amid Stock Surge and Concerns

2/26/2026

50 12 Full Breakdown

Summary

Story summary

The U.S. FDA rejected Atara Biotherapeutics' Ebvallo for post-transplant lymphoproliferative disease (PTLD) due to insufficient clinical data.
The decision came despite internal support and European approval, prompting concerns about FDA consistency under new leadership and a 20% rise in Atara Biotherapeutics' stock.
Ebvallo targets EBV-infected B lymphocytes and had a 48.8% response rate in trials involving more than 430 patients.

1 of 1

Story summary

The U.S. FDA rejected Atara Biotherapeutics' Ebvallo for post-transplant lymphoproliferative disease (PTLD) due to insufficient clinical data.
The decision came despite internal support and European approval, prompting concerns about FDA consistency under new leadership and a 20% rise in Atara Biotherapeutics' stock.
Ebvallo targets EBV-infected B lymphocytes and had a 48.8% response rate in trials involving more than 430 patients.